Chofoza lapha ukuze ubonise izibhengezo ZAKHO kuleli khasi futhi ukhokhele impumelelo kuphela

Izindaba Zocingo

Ukwelashwa Okugunyaziwe Kwe-Myeloma Ephindaphinda Kabusha kanye neRefractory

Ibhalwe ngu umhleli

E-Australia babalelwa ku-2,400 abantu okutholakala ukuthi unyaka ngamunye bane-myeloma eminingi (MM), futhi cishe iziguli ezingama-20,000 eziphila ne-MM nganoma yisiphi isikhathi. Ngeshwa, iziguli ezingaphezu kwe-1000 zizobulawa yilolu hlobo lomdlavuza wegazi kunoma yimuphi unyaka futhi ngakho-ke izindlela ezintsha zokwelapha ezifana ne-XPOVIO® ziyadingeka.              

I-Antengene Corporation Limited namuhla imemezele ukuthi i-Therapeutic Goods Administration (TGA) yoMnyango Wezempilo Kahulumeni wase-Australia ibhalise i-XPOVIO® (selinexor) ngezinkomba ezimbili: (1) Ngokuhambisana ne-bortezomib ne-dexamethasone (XBd) yokwelashwa kweziguli ezikhulile ezine i-myeloma eminingi (MM) abaye bathola okungenani ukwelashwa okukodwa kwangaphambili kanye (2) ngokuhambisana ne-dexamethasone (Xd) yokwelashwa kweziguli ezikhulile ezine-myeloma eminingi ebuyele emuva kanye/noma ephikisayo (R/R MM) ezithole okungenani ezintathu. Imithi yokwelapha yangaphambilini futhi isifo sayo siphikisana okungenani ne-proteasome inhibitor (PI), okungenani umkhiqizo owodwa wokwelapha ovikela umzimba (IMiD), kanye ne-anti-CD38 monoclonal antibody (mAb).

I-XPOVIO® ingeyokuqala futhi iyodwa i-SINE egunyazwe i-TGA esiza ukubuyisela imigudu yokucindezela isimila emzimbeni.

USolwazi Hang Quach, Udokotela Wegazi eSibhedlela sase-St Vincent, eMelbourne, waphawula, “Ngaba nenhlanhla yokuba ngomunye wabaphenyi ocwaningweni lomtholampilo lwase-BOSTON futhi kusukela lapho ngibhale ngokuhlanganyela emaphepheni ambalwa ohlobo lwe-XBd. Lolu hlobo lwemithi emithathu akungabazeki ukuthi engqondweni yami luphakathi kwezindlela zokwelapha eziphumelela kakhulu zokubuyela emuva esikhathini se-lenalidomide refractoriness. Ekuhlaziyweni kwesethi encane, lolu hlobo lwemithi oluthathu lusebenza ngempumelelo kungakhathaliseki ubudala, iziguli ezibuthaka noma ezingekho buthakathaka futhi lusebenza kahle ezigulini ezinemvume ephansi ye-creatinine. Okubalulekile, inhlanganisela ye-XBd yayisebenza ngokukhethekile ezigulini ezine-cytogenetics eyingozi kakhulu.

USolwazi Hang Quach uqhube wathi “Ngikholwa ukuthi imigqa emithathu yokuqala yokwelapha ku-MM ibaluleke kakhulu ekunqumeni ukusinda sisonke kwesiguli ngoba iningi leziguli ezine-MM esimweni somhlaba wangempela ngeke ziphile ukuze zibone umugqa wesine wokwelashwa noma ngale. Ngaphezu kwalokho, inzuzo enkulu kakhulu yomtholampilo itholakala lapho ukwelashwa okuphumelelayo kusetshenziswa ekubuyeni komugqa wokuqala. Ngakho-ke kubalulekile ukuthi udokotela anikezwe ukukhetha okwanele kuleyo ndawo “yomugqa owodwa kuya kwemithathu yangaphambili” ukuze avumele uhlobo lomuthi olufaneleka kakhulu ukuba lusetshenziswe ngokusekelwe kuphrofayili yomtholampilo yesiguli. Ukuntuleka kokukhetha okwanele kweziguli eziphikisayo ze-lenalidomide ekubuyeni kabusha komugqa wangaphambi kwesikhathi kwe-MM kuyindawo yesidingo esingahlangatsheziwe e-Australia. Ukutholakala kwe-XPOVIO®, i-bortezomib ne-dexamethasone njengenketho kulesi sikhala kuzobhekana nalesi sidingo esingafezeki.

“E-Australia, indawo eyodwa ebalulekile yesidingo esingafezeki seziguli ezine-myeloma ukushoda kwezindlela zokwelapha ezisebenzayo ezigulini ezine-triple class refractory, ephikisana ne-proteasome inhibitor, isidakamizwa esivimbela ukuzivikela komzimba kanye ne-anti-CD38 monoclonal antibody. Inzuzo ye-XPOVIO® ukuthi iwumuthi odluliselwa ngomlomo onendlela entsha yokusebenza ewenza ifaneleke ezigulini ezinezigaba ezintathu ezingaguquki. I-XPOVIO® ingakwazi ukuletha izimpendulo futhi yelule impilo ngendlela enenjongo yomtholampilo,” kusho uSolwazi Andrew Spencer, I-Hematologist, i-Alfred Hospital, eMelbourne.

UHayley Beer, i-Interim Co-CEO ye-Myeloma Australia, uthe “Kubaluleke kakhulu ukuba nenye indlela yokwelapha abantu abaphila ne-myeloma eminingi, emigqeni yokwelashwa yangaphambili nakamuva. I-XPOVIO® iwuhlobo olusha lomuthi olunendlela yokusebenza eyingqayizivele, ngakho kusho ukuthi iziguli zingazama inhlanganisela entsha ngaphandle kokwenza kabusha isigaba somuthi esasisetshenziswa ngaphambilini.”

“Lesi yingqophamlando ku-Antengene kanye nasezigulini ze-MM e-Australia. Sijabula kakhulu ngokwethula i-XPOVIO® futhi silethe odokotela neziguli zase-Australia isengezo esisha ezinhlotsheni zabo ezikhona zokwelashwa kwe-R/R MM. Njengomkhiqizo wethu wokuqala ukubhaliswa e-Australia, iphinde ibonise ukuvela kwe-Antengene e-Australia ibe yinhlangano ye-biopharmaceutical ngokuzibophezela ekuthuthukisweni okuqhubekayo kanye nokudayiswa kwemithi yokuguqula umdlavuza nezinye izifo ezisongela ukuphila e-Australia, "kusho uThomas Karalis. I-CVP Asia Pacific yase-Antengene.

“Uchungechunge lwemvume olunikezwe i-XPOVIO® e-China, South Korea, Singapore futhi manje e-Australia ezinyangeni eziyisithupha ezedlule lubonise amandla amakhulu okwelapha alo muthi. E-Australia, babalelwa ku-2,400 abantu abatholakala benesifo sofuba njalo ngonyaka, ngaleyo ndlela baveze isidingo esiphuthumayo esingahlangatshezwana nokwelashwa kwe-MM,” kusho u-Jay Mei, uMsunguli, uSihlalo kanye noMphathi Omkhulu we-Antengene. “Lokhu kugunyazwa yi-TGA kuyashintsha iziguli e-Australia osekunesikhathi eside ziphethwe yi-MM. Sizibophezele ekuletheni izidakamizwa nemithi emisha ezigulini ezinomdlavuza noma ezinye izifo ezisongela ukuphila esifundeni sase-Asia Pacific nasemhlabeni jikelele. Manje, ithimba lethu lezentengiselwano likulungele kahle ukunweba ukufinyelela kweziguli kulokhu kwelashwa kwenoveli, lisakhela phezu kokuhlangenwe nakho kwethu kwezentengiselwano ngokwethulwa kwe-XPOVIO® eChina, eSingapore naseNingizimu Korea.”

Izindaba ezihlobene

Mayelana umbhali

umhleli

Umhleli omkhulu we-eTurboNew nguLinda Hohnholz. Uzinze e-eTN HQ e-Honolulu, e-Hawaii.

Shiya amazwana

Yabelana ku...